Cargando…

WHO SHOULD RECEIVE RADIOTHERAPY IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER?

The standard of treatment of metastatic hormone-sensitive prostate cancer (mHSPC) is androgen deprivation therapy (ADT) with docetaxel or abiraterone. However, numerous retrospective studies suggested outcome benefit of prostate radiotherapy. Small randomized trial (HORRAD) showed no overall surviva...

Descripción completa

Detalles Bibliográficos
Autor principal:	Bišof, Vesna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sestre Milosrdnice University Hospital and Institute of Clinical Medical Research, Vinogradska cesta c. 29 Zagreb 2019
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693553/ https://www.ncbi.nlm.nih.gov/pubmed/34975196 http://dx.doi.org/10.20471/acc.2019.58.s2.06

Ejemplares similares

WHO SHOULD RECEIVE NOVEL HORMONAL THERAPY WITH ANDROGEN DEPRIVATION THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER?
por: Omrčen, Tomislav
Publicado: (2019)

Metastatic hormone-sensitive prostate cancer: How should it be treated?
por: López-Campos, Fernando, et al.
Publicado: (2021)

Prostate radiotherapy for metastatic hormone sensitive prostate cancer—myth or reality?
por: Onal, Cem
Publicado: (2019)

Outcomes of Older Men Receiving Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer
por: Lage, Daniel E., et al.
Publicado: (2021)

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis
por: Burdett, Sarah, et al.
Publicado: (2019)

Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer
por: Cattrini, Carlo, et al.
Publicado: (2019)

Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer
por: Shenoy, Niraj, et al.
Publicado: (2016)

Hormonal Intensification Should Start at the Low-risk Stage in Metastatic Prostate Cancer
por: Jazayeri, Seyed Behzad, et al.
Publicado: (2022)

Radiotherapy for hormone-sensitive prostate cancer with synchronous low burden of distant metastases
por: Müller, Arndt-Christian, et al.
Publicado: (2022)

Metastatic Hormone-sensitive Prostate Cancer: Current Perspective on the Evolving Therapeutic Landscape
por: Hall, Mary E, et al.
Publicado: (2020)

Systemic therapies for metastatic hormone‐sensitive prostate cancer: network meta‐analysis
por: Mori, Keiichiro, et al.
Publicado: (2021)

Advancements in the treatment of metastatic hormone-sensitive prostate cancer
por: Li, Hengping, et al.
Publicado: (2022)

ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer?
por: Kumar, Naveen
Publicado: (2022)

Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
por: Lee, Arnold
Publicado: (2023)

Discussion of Treatment Options for Metastatic Hormone Sensitive Prostate Cancer Patients
por: Sigurdson, Samantha S., et al.
Publicado: (2020)

Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice
por: de Groot, Ietsen, et al.
Publicado: (2021)

Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice
por: Lendorf, Maria Elisabeth, et al.
Publicado: (2021)

Prognostic Impact of Sarcopenia in Patients with Metastatic Hormone-Sensitive Prostate Cancer
por: Lee, Ji Hyun, et al.
Publicado: (2021)

Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
por: Armstrong, Andrew J., et al.
Publicado: (2022)

SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC)
por: Omrčen, Tomislav
Publicado: (2022)

Correction to: Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
por: Lee, Arnold
Publicado: (2023)

Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer
por: Chen, Kenneth, et al.
Publicado: (2022)

Satraplatin in the treatment of hormone-refractory metastatic prostate cancer
por: Armstrong, Andrew J, et al.
Publicado: (2007)

Abiraterone acetate in combination with prednisone in the treatment of metastatic hormone-sensitive prostate cancer: clinical evidence and experience
por: Purshouse, Karin, et al.
Publicado: (2019)

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting
por: Ng, Kenrick, et al.
Publicado: (2020)

Radiotherapy combined with hormonal therapy in prostate cancer: the state of the art
por: Milecki, Piotr, et al.
Publicado: (2010)

Role of circulating tumor cell clusters in patients with metastatic hormone-sensitive prostate cancer receiving a gonadotropin-releasing hormone antagonist: A pilot study
por: Kohada, Yuki, et al.
Publicado: (2023)

IMPACT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY ON THE QUALITY OF LIFE IN CANCER PATIENTS
por: Novak, Marica, et al.
Publicado: (2022)

Prognostic Factors for Hormone Sensitive Metastatic Prostate Cancer: Impact of Disease Volume
por: Alhanafy, Alshimaa Mahmoud, et al.
Publicado: (2018)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
por: Talwar, Harkirat Singh
Publicado: (2021)

Combination therapy in metastatic hormone-sensitive prostate cancer: is three a crowd?
por: Davis, Ian D.
Publicado: (2022)

Hormonal Therapy in Metastatic Prostate Cancer: Current Perspectives and Controversies
por: Garg, Manish, et al.
Publicado: (2013)

Novel metastatic burden‐stratified risk model in de novo metastatic hormone‐sensitive prostate cancer
por: Shiota, Masaki, et al.
Publicado: (2021)

Debate on Treating Oligometastatic Metastatic Hormone-sensitive Prostate Cancer: The Argument for New-generation Hormone Therapy and Radiation Therapy to the Prostate
por: Saad, Fred
Publicado: (2022)

WHICH PATIENTS SHOULD RECEIVE RADIOTHERAPY IN POSTOPERATIVE DISEASE RECURRENCE?
por: Matić, Mate, et al.
Publicado: (2019)

THE MULTIDISCIPLINARY TEAM (MDT) IN THE TREATMENT OF HEAD AND NECK CANCER – A SINGLE-INSTITUTION EXPERIENCE
por: Prgomet, Drago, et al.
Publicado: (2022)

Systemic Triple Therapy in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Ready for Prime Time or Still to Be Explored?
por: Thomas, Christian, et al.
Publicado: (2021)

Fatal outcome of posterior “reversible” encephalopathy syndrome in metastatic colorectal carcinoma after irinotecan and fluoropyrimidine chemotherapy regimen
por: Dedić Plavetić, Natalija, et al.
Publicado: (2014)

A Cost-Effectiveness Analysis of Systemic Therapy for Metastatic Hormone-Sensitive Prostate Cancer
por: Sung, Winnie W. Y., et al.
Publicado: (2021)

Editorial Comment: Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer
por: Lott, Felipe
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3vcdibpv5lvl35j40un63m204m